Our results showing that FLT3 mutations lead to overexpression and/or activation of FLT3 in both the GL-1 cell line and clinical canine ALL cases is similar to findings examining human ALL cell lines and infant/childhood ALL, although the mechanism of activation more resembles that in human AML (i.e. ITD mutation). This evidence concerns the gene FLT3 and acute myeloid leukemia.